Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy.
Li X, Eastham J, Giltnane JM, Zou W, Zijlstra A, Tabatsky E, Banchereau R, Chang CW, Nabet BY, Patil NS, Molinero L, Chui S, Harryman M, Lau S, Rangell L, Waumans Y, Kockx M, Orlova D, Koeppen H.
Li X, et al.
J Pathol. 2024 Jun;263(2):190-202. doi: 10.1002/path.6274. Epub 2024 Mar 25.
J Pathol. 2024.
PMID: 38525811